Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia

Journal of Infection and Chemotherapy

Volumn 11, Issue 1, 2005, Pages 52-54

  Okimoto, Niro ^a   Yamato, Kenji ^a   Honda, Yoshihiro ^a   Kurihara, Takeyuki ^a   Osaki, Kohichi ^a   Asaoka, Naoko ^a   Fujita, Kazue ^a   Ohba, Hideo ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Ciprofloxacin; Hospital acquired pneumonia; Intravenous fluoroquinolones

Indexed keywords

CIPROFLOXACIN; METICILLIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; ERADICATION THERAPY; FEMALE; HUMAN; KLEBSIELLA OXYTOCA; LABORATORY TEST; MALE; PENICILLIN RESISTANCE; PNEUMONIA; SIDE EFFECT; STAPHYLOCOCCUS AUREUS;

EID: 15044359070     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0364-9     Document Type: Article

References (12)

1. The Committee for the Japanese Respiratory Society Guidelines in Management of Respiratory Infections. The Japanese Respiratory Society guidelines for management of hospital-acquired pneumonia (in Japanese). Tokyo: Kyorinsya; 2002. p. 27-34.
2. The report of the Committee for the Respiratory System, the Committee of Clinical Evaluation Methods for Antibiotics, Japanese Society of Chemotherapy. Clinical evaluation method for new antimicrobial agents to treat respiratory infections (draft; in Japanese). Jpn J Chemother 1997;45:762-78.
3. Okimoto N, Kurihara T, Honda Y, Asaoka N, Fujita K, Ohba H, et al. Clinical evaluation of injectable ciprofloxacin in poor responders to carbapenems and injectable third-generation cephems (in Japanese). Jpn J Chemother 2002;5:280-2.
4. Kobashi Y, Fujita K, Karino T, Yano T, Nakamura J, Okimoto N. Clinical analysis of pneumonia in the elderly in a community hospital - comparison of community-acquired pneumonia and nosocomial pneumonia (in Japanese). Kansenshogaku Zasshi 1999;73: 884-92.
5. Kikuchi N, Onozaki I, Kohno N, Yamaguchi T, Nagao K, Kuriyama T, et al. Clinical evaluation of therapy for pulmonary infection with imipenem cilastatin sodium. Monotherapy with imipenem cilastatin sodium of moderate and severe pneumonia (in Japanese). Jpn J Chemother 1990;38:74-89.
6. Fink MP, Snydma DR, Niederman MS, Leeper KV, Johnson R, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-57.
7. Torres A, Bauer TT, Leon-il C, Catillo F, Alvarez-Lerma F, Martinez-Pellus A, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-9.
8. Saginur R, Garber G, Darling G, Shafran S, Cameron W, Jones G, et al. Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia. Can J Infect Dis 1997;8:89-94.
9. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7.
10. Davis R, Markham A, Balfour JA. Ciprofloxacin - an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019-74.
11. Yamaguchi K, Isii Y, Yamanaka K, Watanabe N, Uehara N, Kaku M, et al. Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections - the first Ciproxan® iv special investigation in 2001 (in Japanese). Jpn J Antibiot 2003;56:546-73.
12. Fujita M, Yoshida M, Ishibashi T, Hara N, Yamada H. The effect of intravenous ciprofloxacin for community acquired pneumonia in adults. Jpn J Antibiot 2003;56:289-93.